Thrombopoietin
Thrombopoietin (TPO) is a glycoprotein hormone and the key regulator of platelet production (thrombopoiesis). It stimulates the differentiation of hematopoietic stem cells into megakaryocyte progenitors and drives their maturation into platelet-producing megakaryocytes. TPO is synthesized primarily in the liver parenchyma, with minor contributions from the kidney and bone marrow stromal cells. It exerts its effect via the thrombopoietin receptor (c-MPL), activating downstream signaling pathways including JAK-STAT, PI3K-AKT, and MAPK, which promote megakaryocyte proliferation and platelet release.
Deficiency of thrombopoietin either by genetic mutations of the TPO gene or by acquired etiology (e.g.: liver cirrhosis) can result in severe decline in platelet count leading to thrombocytopenia. In some circumstances, despite adequate thrombopoietin synthesis, the deficiency of thrombopoietin receptors due to MPL gene mutations can lead to congenital amegakaryocytic thrombocytopenia (CAMT) and affected individuals exhibit severe thrombocytopenia at birth. In this case, the thrombopoietin levels in blood is increased since there is little clearance. On the other hand, excess thrombopoietin activity due to activating mutations can lead to thrombocytosis and increase in other blood cells populations leading to essential thrombocythemia, polycythemia, myelodysplastic syndromes, and aplastic anemia. Measurement of TPO can assist in differentiating marrow failure from peripheral causes of thrombocytopenia and in monitoring liver function, as hepatic impairment reduces TPO synthesis.
- Investigating the etiology of unexplained thrombocytopenia or thrombocytosis
- Differentiating bone marrow failure syndromes from peripheral platelet destruction
- Monitoring response to thrombopoietin receptor agonists (e.g., eltrombopag, romiplostim)
- Supporting diagnosis in congenital thrombocytopenia (e.g., CAMT)
Increased in:
- Aplastic anemia
- Myelodysplastic syndromes
- Congenital amegakaryocytic thrombocytopenia (CAMT)
- Severe thrombocytopenia with impaired receptor-mediated clearance
Decreased in:
- Thrombocytopenia
- Reactive thrombocytosis
- Liver cirrhosis/failure
- thrombocytopenia (CAMT)
7 – 99 pg/mL
Chemiluminescent immunoassay, enzyme immunoassay, enzyme-linked immunosorbent assay (ELISA).
Serum, SST.
Stability
- Ambient: unacceptable
- Refrigerated: unacceptable
- Frozen: 1 month
- Blood. 1995 Jul 15;86(2):419-31. [PMID: 7605981]
- Int J Hematol. 1999 Dec;70(4):216-25. [PMID: 10643146]
- Pediatr Blood Cancer. 2011 Aug;57(2):199-203. Epub 2011 Feb 18. [PMID: 21337678]
- Hepat Mon. 2014 May 5;14(5):e18556. [PMID: 24976834]
- Int J Hematol. 2013 Jul;98(1):10-23. [PMID: 23821332]
- J Thromb Haemost. 2003 Jul;1(7):1587-92. [PMID: 12871295]